LISINOPRIL (TYPE Z) 10 MG
LISINOPRIL : 10 MG · DIN 02525194 · SANIS HEALTH INC
Health Canada status: MARKETED
What is LISINOPRIL (TYPE Z)?
LISINOPRIL (TYPE Z) 10 MG contains LISINOPRIL : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02525194, held by SANIS HEALTH INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Mar-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LISINOPRIL (TYPE Z) used for?
Treatment of essential and renovascular hypertension; management of symptomatic congestive heart failure (adjunctive); improvement of survival in hemodynamically stable patients after acute MI.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02525194 |
|---|---|
| Brand name | LISINOPRIL (TYPE Z) |
| Generic / active ingredient | LISINOPRIL : 10 MG |
| Manufacturer | SANIS HEALTH INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA03 LISINOPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Mar-2025 |
| Original market date | 2022-04-12 00:00:00 |
How is it administered?
Individualize dose. Hypertension: 10-40 mg once daily. Heart Failure: Start 2.5 mg daily, max 35 mg. Acute MI: 5 mg initially, then 5 mg at 24h, 10 mg at 48h, then 10 mg daily.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (standard section 11 was listed in TOC but text cut off). Typically 15-30°C.
How is it supplied?
5 mg and 10 mg: Bottles of 100, blister packs of 30. 20 mg: Bottles of 100 and 500, blister packs of 30.
Contraindications
Hypersensitivity to ACE inhibitors; history of angioedema; pregnancy/nursing; concomitant use with sacubitril/valsartan or aliskiren (in diabetes/renal impairment); children <6 years.
Warnings and precautions
Risk of hypotension (especially volume depleted), angioedema, hyperkalemia, and neutropenia. Dual blockade of RAS increases risk of hypotension and renal impairment.
What can be used instead?
Other Canadian products sharing ATC code C09AA03 LISINOPRIL. 15 of 99 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-LISINOPRIL | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02394480 |
| AURO-LISINOPRIL | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02394499 |
| AURO-LISINOPRIL | 5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02394472 |
| LISINOPRIL (TYPE Z) | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02525208 |
| LISINOPRIL (TYPE Z) | 5 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02525186 |
| LISINOPRIL TABLETS | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02554496 |
| LISINOPRIL TABLETS | 20 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02554518 |
| LISINOPRIL TABLETS | 5 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02554488 |
| TEVA-LISINOPRIL (TYPE Z) | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02285126 |
| TEVA-LISINOPRIL (TYPE Z) | 20 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02285134 |
Who else supplies LISINOPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LISINOPRIL appears in 493 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.